Oppenheimer & CO Inc Nuvectis Pharma, Inc. Transaction History
Oppenheimer & CO Inc
- $6.52 Billion
- Q4 2024
A detailed history of Oppenheimer & CO Inc transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 25,000 shares of NVCT stock, worth $167,250. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,000Holding current value
$167,250% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NVCT
# of Institutions
32Shares Held
1.9MCall Options Held
0Put Options Held
0-
Ronit Capital LLP563KShares$3.76 Million5.37% of portfolio
-
Baldwin Brothers LLC356KShares$2.38 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA325KShares$2.18 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0125KShares$833,3790.0% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$558,0260.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $98M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...